Related Experiment Video
Updated: Jul 10, 2026

05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Evaluation of breast sentinel lymph node coverage by standard radiation therapy fields
Rachel Rabinovitch1, Ari Ballonoff, Francis Newman
1Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA. Rachel.rabinovitch@uchsc.edu
International Journal of Radiation Oncology, Biology, Physics
|October 31, 2007
Summary
Sentinel lymph node (SLN) biopsy is standard for early breast cancer staging. Standard radiation fields often exclude the SLN, potentially missing high-risk lymph nodes, but adjustments can improve coverage.
Area of Science:
- Oncology
- Radiotherapy
- Surgical Oncology
Background:
- Sentinel lymph node (SLN) biopsy is a standard staging procedure for early-stage invasive breast cancer.
- The anatomical location of breast SLNs and their relation to radiation fields are not well-described.
Purpose of the Study:
- To describe the anatomical location of breast sentinel lymph nodes (SLNs) relative to standard radiotherapy fields.
- To assess the coverage of SLNs by standard whole-breast and axillary radiation fields in breast cancer patients.
Main Methods:
- Retrospective review of radiotherapy treatment planning data for 106 breast cancer patients who underwent SLN biopsy.
- Evaluation of SLN clip location relative to vertebral body level, whole-breast tangential fields, and standard axillary fields.
Main Results:
- Breast SLNs were most commonly located opposite the T4 vertebral body level (range T2-T7).
- 90% of SLN clips were below the clavicle, excluding them from standard axillary fields.
- 78% of SLN clips were within whole-breast tangent fields, but 10% were outside.
Conclusions:
- Standard axillary radiotherapy fields do not adequately cover the highest-risk lymph nodes in breast cancer patients.
- Modifying tangent field design to exclude superior-posterior multileaf collimators could include SLNs in 90% of patients.